Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Pharming Group N.V.
  6. Summary
    PHARM   NL0010391025

PHARMING GROUP N.V.

(PHARM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
0.9228(c) 0.9364(c) 0.9674(c) 0.972(c) 0.967(c) Last
1 756 958 1 557 639 2 808 287 2 298 994 1 401 409 Volume
-0.02% +1.47% +3.31% +0.48% -0.51% Change
More quotes
Estimated financial data (e)
Sales 2021 183 M 216 M 216 M
Net income 2021 35,3 M 41,7 M 41,7 M
Net cash position 2021 42,1 M 49,7 M 49,7 M
P/E ratio 2021 18,8x
Yield 2021 -
Sales 2022 240 M 284 M 284 M
Net income 2022 57,4 M 67,8 M 67,8 M
Net cash position 2022 71,1 M 83,9 M 83,9 M
P/E ratio 2022 12,4x
Yield 2022 -
Capitalization 625 M 738 M 737 M
EV / Sales 2021 3,19x
EV / Sales 2022 2,30x
Nbr of Employees 262
Free-Float 98,0%
More Financials
Company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core... 
Sector
Pharmaceuticals
Calendar
08/05 | 01:00amEarnings Release
More about the company
Ratings of Pharming Group N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PHARMING GROUP N.V.
07/20PHARMING N : signs agreement with NewBridge Pharmaceuticals for the commercializ..
PU
07/20Pharming Signs Agreement with Newbridge Pharmaceuticals for the Commercializa..
CI
07/01ORCHARD THERAPEUTICS : to Collaborate With Pharming Group on Treatment for Hered..
MT
07/01PHARMING N : Orchard Therapeutics and Pharming Group Announce Collaboration to D..
PU
07/01ORCHARD THERAPEUTICS : and Pharming Group Announce Collaboration to Develop and ..
AQ
07/01Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and..
CI
07/01Orchard Therapeutics plc announced that it expects to receive $7.5 million in..
CI
06/23PHARMING N : Pharming announces completion of enrolment in Phase II/III study wi..
PU
06/23PHARMING N : announces completion of enrolment in Phase II/III study with leniol..
PU
06/23Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study wi..
CI
06/21PHARMING GROUP N.V.(ENXTAM : PHARM) added to Netherlands ASCX AMS Small Cap Inde..
CI
06/18PHARMING N : appoints Anurag Relan as Chief Medical Officer and Robert Friesen a..
PU
06/18Pharming Group N.V. Announces Executive Changes
CI
06/18PHARMING GROUP N.V.(ENXTAM : PHARM) dropped from AMX Index
CI
06/04PHARMING N : announces the reimbursement of RUCONEST« in Spain
PU
More news
News in other languages on PHARMING GROUP N.V.
07/20Pharming vindt partner voor Ruconest in Midden-Oosten en Afrika
07/01AEX overtuigend hoger
07/01AMSTERDAM STOCK EXCHANGE : AEX hoger van start gegaan
07/01UPDATE : Pharming kondigt samenwerking met Orchard Therapeutics aan
07/01Pharming kondigt samenwerking met Orchard Therapeutics aan
More news
Chart PHARMING GROUP N.V.
Duration : Period :
Pharming Group N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMING GROUP N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,97 €
Average target price 2,21 €
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Sijmen de Vries Chief Executive Officer & Executive Director
Jeroen Henk Wakkerman Chief Financial Officer
Paul Jai Sekhri Chairman
Anurag Relan Chief Medical Officer
Mireille Sanders Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
PHARMING GROUP N.V.-23.58%728
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246